JP2017520763A - 肝臓癌の非侵襲性診断のための特異的バイオマーカーセット - Google Patents

肝臓癌の非侵襲性診断のための特異的バイオマーカーセット Download PDF

Info

Publication number
JP2017520763A
JP2017520763A JP2016571689A JP2016571689A JP2017520763A JP 2017520763 A JP2017520763 A JP 2017520763A JP 2016571689 A JP2016571689 A JP 2016571689A JP 2016571689 A JP2016571689 A JP 2016571689A JP 2017520763 A JP2017520763 A JP 2017520763A
Authority
JP
Japan
Prior art keywords
protein
tumor
autoantibodies
biomarker
bead
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016571689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520763A5 (enExample
Inventor
コルネリア ウィン イン マン
コルネリア ウィン イン マン
ノーマン ファン マン ウァイ
ノーマン ファン マン ウァイ
ベンジャミン チー イン ウァイ
ベンジャミン チー イン ウァイ
ビン ルー ウォン
ビン ルー ウォン
Original Assignee
ドラゴン ヴィクトリー ディベロップメント リミテッド
ドラゴン ヴィクトリー ディベロップメント リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/321,867 external-priority patent/US9506925B2/en
Priority claimed from US14/321,870 external-priority patent/US9885718B2/en
Application filed by ドラゴン ヴィクトリー ディベロップメント リミテッド, ドラゴン ヴィクトリー ディベロップメント リミテッド filed Critical ドラゴン ヴィクトリー ディベロップメント リミテッド
Publication of JP2017520763A publication Critical patent/JP2017520763A/ja
Publication of JP2017520763A5 publication Critical patent/JP2017520763A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2016571689A 2014-07-02 2014-07-31 肝臓癌の非侵襲性診断のための特異的バイオマーカーセット Pending JP2017520763A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/321,870 2014-07-02
US14/321,867 US9506925B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
US14/321,870 US9885718B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
US14/321,867 2014-07-02
PCT/US2014/049038 WO2016003479A1 (en) 2014-07-02 2014-07-31 Specific biomarker set for non-invasive diagnosis of liver cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020106731A Division JP2020160082A (ja) 2014-07-02 2020-06-22 肝臓癌の非侵襲性診断のための特異的バイオマーカーセット

Publications (2)

Publication Number Publication Date
JP2017520763A true JP2017520763A (ja) 2017-07-27
JP2017520763A5 JP2017520763A5 (enExample) 2017-09-21

Family

ID=55019816

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016571689A Pending JP2017520763A (ja) 2014-07-02 2014-07-31 肝臓癌の非侵襲性診断のための特異的バイオマーカーセット
JP2020106731A Withdrawn JP2020160082A (ja) 2014-07-02 2020-06-22 肝臓癌の非侵襲性診断のための特異的バイオマーカーセット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020106731A Withdrawn JP2020160082A (ja) 2014-07-02 2020-06-22 肝臓癌の非侵襲性診断のための特異的バイオマーカーセット

Country Status (12)

Country Link
EP (1) EP3164711A4 (enExample)
JP (2) JP2017520763A (enExample)
KR (1) KR102086788B1 (enExample)
CN (2) CN105319362B (enExample)
AU (2) AU2014399919B2 (enExample)
CA (1) CA2939912C (enExample)
MY (2) MY195045A (enExample)
NZ (1) NZ722492A (enExample)
SG (1) SG11201606106SA (enExample)
TW (1) TWI700493B (enExample)
UY (1) UY36200A (enExample)
WO (1) WO2016003479A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106383231B (zh) * 2016-09-02 2020-03-17 四川大学 一种诊断肝癌的标记物组合及其应用
GB201619954D0 (en) * 2016-11-25 2017-01-11 Oncimmune Ltd Antibody assay
KR102175265B1 (ko) 2019-03-13 2020-11-06 충남대학교산학협력단 Txndc7을 포함하는 간세포암종 진단 또는 예후 예측용 바이오마커 조성물
CN110646615B (zh) * 2019-08-27 2021-07-13 南方医科大学 肝纤维化的生物学标志物、治疗靶点及其用途
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
ES2987661T3 (es) 2020-07-10 2024-11-15 Guardant Health Inc Métodos de detección de reordenamientos genómicos utilizando ácidos nucleicos libres de células
CN113502328A (zh) * 2021-05-27 2021-10-15 深圳市人民医院 检测样本中标志物表达水平的试剂在制备用于检测或诊断乳腺癌的试剂盒中的应用
CN113777295B (zh) * 2021-09-15 2024-03-19 江南大学 用于检测肿瘤标志物pd-l1的高灵敏度量子点探针、制备方法及应用
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
CN114113611B (zh) * 2021-12-13 2023-07-14 郑州大学 一种用于肝癌诊断的生物标志物及检测试剂盒

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052392A2 (en) * 2002-12-11 2004-06-24 The University Of Birmingham Cancer immunotherapy using polycomb proteins
JP2005099001A (ja) * 2003-08-31 2005-04-14 Kyogo Ito 抗ペプチド抗体測定法とペプチドワクチンのワクチン候補選択方法
JP2008502891A (ja) * 2004-06-18 2008-01-31 エフ．ホフマン−ラ　ロシュ　アーゲー 乳癌のマーカーとしてのタンパク質ｐｄｘ１の使用
JP2008026290A (ja) * 2006-07-25 2008-02-07 Ehime Univ 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法
JP2012047543A (ja) * 2010-08-25 2012-03-08 Yamaguchi Univ 自己抗体の検出方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6449562B1 (en) * 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
US6893844B1 (en) * 1998-09-22 2005-05-17 Long Yu DNA encoding a new human hepatoma derived growth factor and producing method thereof
US7387881B2 (en) * 2001-09-19 2008-06-17 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
AU2002361908A1 (en) * 2001-12-31 2003-07-24 Quark Biotech, Inc. Methods for identifying marker genes for cancer
GB0406215D0 (en) * 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
KR20100040964A (ko) * 2007-08-10 2010-04-21 가꼬우호우징 효고 이카다이가쿠 신규 간암 마커
US8512963B2 (en) * 2009-11-25 2013-08-20 The Johns Hopkins University Detection and quantitation of full-length thioredoxin (TRX) and truncated thioredoxin (TRX 80) in complex samples
US9523680B2 (en) * 2010-06-30 2016-12-20 Ambergen, Inc. Global Proteomic screening of random bead arrays using mass spectrometry imaging
EP2678448A4 (en) * 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS
US20130130355A1 (en) * 2011-09-28 2013-05-23 Armune Biosciences, Inc. Method and system of particle-phage epitope complex

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052392A2 (en) * 2002-12-11 2004-06-24 The University Of Birmingham Cancer immunotherapy using polycomb proteins
JP2005099001A (ja) * 2003-08-31 2005-04-14 Kyogo Ito 抗ペプチド抗体測定法とペプチドワクチンのワクチン候補選択方法
JP2008502891A (ja) * 2004-06-18 2008-01-31 エフ．ホフマン−ラ　ロシュ　アーゲー 乳癌のマーカーとしてのタンパク質ｐｄｘ１の使用
JP2008026290A (ja) * 2006-07-25 2008-02-07 Ehime Univ 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法
JP2012047543A (ja) * 2010-08-25 2012-03-08 Yamaguchi Univ 自己抗体の検出方法

Also Published As

Publication number Publication date
EP3164711A1 (en) 2017-05-10
AU2017232129B2 (en) 2018-10-25
NZ722492A (en) 2019-09-27
CN107478842B (zh) 2020-10-16
UY36200A (es) 2016-01-29
AU2014399919B2 (en) 2019-10-24
WO2016003479A1 (en) 2016-01-07
KR20170021234A (ko) 2017-02-27
HK1224370A1 (zh) 2017-08-18
CN107478842A (zh) 2017-12-15
CA2939912A1 (en) 2016-01-07
CA2939912C (en) 2019-04-16
EP3164711A4 (en) 2018-05-23
MY195045A (en) 2023-01-04
CN105319362B (zh) 2018-07-13
TWI700493B (zh) 2020-08-01
HK1248803A1 (zh) 2018-10-19
SG11201606106SA (en) 2016-08-30
CN105319362A (zh) 2016-02-10
JP2020160082A (ja) 2020-10-01
AU2017232129A1 (en) 2017-10-12
AU2014399919A1 (en) 2016-08-11
TW201602579A (zh) 2016-01-16
KR102086788B1 (ko) 2020-03-09
MY179845A (en) 2020-11-18

Similar Documents

Publication Publication Date Title
JP2020160082A (ja) 肝臓癌の非侵襲性診断のための特異的バイオマーカーセット
JP6639408B2 (ja) デオキシハイプシン・シンターゼ遺伝子を指標として用いる動脈硬化及びがんの検出方法
US20200386761A1 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
Hu et al. High RSF-1 expression correlates with poor prognosis in patients with gastric adenocarcinoma
JP6361943B2 (ja) 補体因子ｂタンパク質に特異的に結合する抗体及び糖鎖抗原１９−９タンパク質に特異的に結合する抗体を含む膵臓癌診断用キット
KR102713301B1 (ko) 췌장암 및 췌장관 내 유두상 점액성 종양의 마커
US10620209B2 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
Kikuchi et al. Reduced serum vascular endothelial growth factor receptor‐2 (sVEGFR‐2) and sVEGFR‐1 levels in gastric cancer patients
EP3215851A2 (en) Lung cancer sub-typing method
US9885718B2 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
JP7432578B2 (ja) がんマーカーおよびその用途
JP5358808B2 (ja) 腫瘍マーカー、腫瘍診断キット、腫瘍マーカーの測定方法および腫瘍診断方法
Salinas et al. Expression of Lumican and Osteopontin in Perivascular Areas of the Glioblastoma Peritumoral Niche and Its Value for Prognosis
JPWO2016143805A1 (ja) 膀胱がんの検出方法
HK1224370B (zh) 用於肝癌的无创诊断的特异性生物标志物组
HK1248803B (zh) 用於肝癌的无创诊断的特异性生物标志物组
CN104142403B (zh) Chip蛋白在胰腺癌早期诊断以及预后判断中的用途
Polanco Comparative Proteomic Analysis Of Extracellular Vesicles From Prostate Cancer-Derived Cell Lines
JP2012225822A (ja) ＡＰＣ−ｂｉｎｄｉｎｇｐｒｏｔｅｉｎＥＢ１を用いた大腸癌の診断、治療法
WO2016005916A1 (en) A method and kit for the detection of a biomarker of thyroid cancer in biological samples
JP2015148480A (ja) がん転移マーカー及びその分析方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170809

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200220